美康生物
(300439)
| 流通市值：28.91亿 | | | 总市值：37.96亿 |
| 流通股本：2.92亿 | | | 总股本：3.84亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,274,484,002.62 | 828,022,677.7 | 376,022,696.88 | 1,539,159,714.69 |
| 营业收入 | 1,274,484,002.62 | 828,022,677.7 | 376,022,696.88 | 1,539,159,714.69 |
| 二、营业总成本 | 1,192,015,917.75 | 787,869,481.45 | 351,135,278.16 | 1,516,898,858.66 |
| 营业成本 | 805,497,536.47 | 534,315,839.56 | 231,437,715.5 | 972,738,132.3 |
| 税金及附加 | 13,736,104.47 | 9,178,355.22 | 4,316,678.96 | 19,075,191.02 |
| 销售费用 | 159,434,421.99 | 100,522,847.4 | 52,650,643.01 | 225,502,634.4 |
| 管理费用 | 119,571,164.97 | 82,184,699.9 | 33,838,780.56 | 173,193,201.12 |
| 研发费用 | 95,199,202.58 | 62,414,940.31 | 28,846,722.25 | 127,196,766.84 |
| 财务费用 | -1,422,512.73 | -747,200.94 | 44,737.88 | -807,067.02 |
| 其中:利息费用 | 1,177,203.44 | 930,051.32 | 152,965.28 | 2,567,315.64 |
| 其中:利息收入 | 2,579,783.1 | 2,685,758.09 | 551,633.04 | 3,875,904.19 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,361,217.55 | 846,461.54 | 756,930.68 | 430,440.4 |
| 加:投资收益 | 11,147,869.44 | 9,697,793.23 | 891,298.04 | 8,724,190.36 |
| 资产处置收益 | 40,180.5 | 1,142.76 | - | 1,659,738.98 |
| 资产减值损失(新) | -1,454,234.96 | -1,090,795.46 | -341,683.06 | -32,934,184.75 |
| 信用减值损失(新) | -5,972,411.96 | -4,079,128.7 | -247,199.37 | -6,820,931.29 |
| 其他收益 | 26,221,682.77 | 22,214,149.42 | 11,663,856.61 | 39,945,112.09 |
| 四、营业利润 | 114,812,388.21 | 67,742,819.04 | 37,610,621.62 | 33,265,221.82 |
| 加:营业外收入 | 217,677.75 | 1,077,189.01 | 5,871.87 | 14,393,470.78 |
| 减:营业外支出 | 5,969,949.26 | 2,381,619.84 | 640,095.25 | 1,566,046.34 |
| 五、利润总额 | 109,060,116.7 | 66,438,388.21 | 36,976,398.24 | 46,092,646.26 |
| 减:所得税费用 | 10,010,749.13 | 4,882,725.6 | 3,788,400.12 | -15,269,330.52 |
| 六、净利润 | 99,049,367.57 | 61,555,662.61 | 33,187,998.12 | 61,361,976.78 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 99,049,367.57 | 61,555,662.61 | 33,187,998.12 | 61,361,976.78 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 97,837,688.82 | 61,949,210.91 | 33,766,362.28 | 63,201,459.62 |
| 少数股东损益 | 1,211,678.75 | -393,548.3 | -578,364.16 | -1,839,482.84 |
| 扣除非经常损益后的净利润 | 80,353,440.33 | 44,239,100.95 | 23,145,176.7 | 15,456,921.15 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.25 | 0.16 | 0.09 | 0.16 |
| (二)稀释每股收益 | 0.25 | 0.16 | 0.09 | 0.16 |
| 八、其他综合收益 | 1,621,964.1 | 1,251,247.48 | 737,416.79 | -628,731.08 |
| 归属于母公司股东的其他综合收益 | 799,730.48 | 620,620.63 | 375,818.74 | -1,014,070.39 |
| 九、综合收益总额 | 100,671,331.67 | 62,806,910.09 | 33,925,414.91 | 60,733,245.7 |
| 归属于母公司股东的综合收益总额 | 98,637,419.3 | 62,569,831.54 | 34,142,181.02 | 62,187,389.23 |
| 归属于少数股东的综合收益总额 | 2,033,912.37 | 237,078.55 | -216,766.11 | -1,454,143.53 |
| 公告日期 | 2026-10-28 | 2026-08-29 | 2026-04-29 | 2026-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |